Drug Profile
Research programme: antithrombotic agents - MediciNova
Alternative Names: MN-447; MN-462Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Meiji Seika Kaisha
- Developer MediciNova
- Class Small molecules
- Mechanism of Action Enzyme inhibitors; GPIIb-IIIa antagonists; Integrin alphaVbeta3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Thrombosis in USA
- 09 Aug 2012 MN 447 and MN 462 are still in Preclinical trials for Thrombosis in USA
- 01 Apr 2011 Meiji Seika Kaisha is now called Meiji Seika Pharma